| 2024年年报 | 2024年中报 | |
|---|---|---|
| 营业收入(元) | ||
| 抗结肠炎药(元) | - | 14,674,159.32 |
| 抗哮喘药(元) | - | 18,211,325.83 |
| 中间体-B6/C6(元) | - | 23,580,345.19 |
| 中间体-其他(元) | - | 18,097.34 |
| 抗结肠炎类(元) | 30,289,336.31 | - |
| 抗哮喘类(元) | 71,226,436.41 | - |
| 营业成本(元) | ||
| 抗结肠炎药(元) | - | 9,082,097.20 |
| 抗哮喘药(元) | - | 7,050,223.90 |
| 中间体-B6/C6(元) | - | 18,503,058.80 |
| 中间体-其他(元) | - | 13,279.42 |
| 抗结肠炎类(元) | 18,746,876.55 | - |
| 抗哮喘类(元) | 43,395,000.37 | - |
| 毛利(元) | ||
| 抗结肠炎药(元) | - | 5,592,062.12 |
| 抗哮喘药(元) | - | 11,161,101.93 |
| 中间体-B6/C6(元) | - | 5,077,286.39 |
| 中间体-其他(元) | - | 4,817.92 |
| 抗结肠炎类(元) | 11,542,459.76 | - |
| 抗哮喘类(元) | 27,831,436.04 | - |
| 毛利率(%) | ||
| 抗结肠炎药(%) | - | 38.11 |
| 抗哮喘药(%) | - | 61.29 |
| 中间体-B6/C6(%) | - | 21.53 |
| 中间体-其他(%) | - | 26.62 |
| 抗结肠炎类(%) | 38.11 | - |
| 抗哮喘类(%) | 39.07 | - |
| 收入构成(%) | ||
| 抗结肠炎药(%) | - | 25.98 |
| 抗哮喘药(%) | - | 32.24 |
| 中间体-B6/C6(%) | - | 41.75 |
| 中间体-其他(%) | - | 0.03 |
| 抗结肠炎类(%) | 29.84 | - |
| 抗哮喘类(%) | 70.16 | - |
| 毛利构成(%) | ||
| 抗结肠炎药(%) | - | 25.61 |
| 抗哮喘药(%) | - | 51.12 |
| 中间体-B6/C6(%) | - | 23.25 |
| 中间体-其他(%) | - | 0.02 |
| 抗结肠炎类(%) | 29.32 | - |
| 抗哮喘类(%) | 70.68 | - |